SRNE — Sorrento Therapeutics, Inc.
$0.00
+$0.00 (+0.00%)
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA.
Market Cap
$165384.00
Forward P/E
N/A
52-Week Range
N/A
SRNE Price History
Revenue vs. Net Income
$62.8M
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$308M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-381.7%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.0x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
21.7%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+42.2%
Dilution · FY2022
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
